EP2331142A4 - Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells - Google Patents

Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells

Info

Publication number
EP2331142A4
EP2331142A4 EP09812189A EP09812189A EP2331142A4 EP 2331142 A4 EP2331142 A4 EP 2331142A4 EP 09812189 A EP09812189 A EP 09812189A EP 09812189 A EP09812189 A EP 09812189A EP 2331142 A4 EP2331142 A4 EP 2331142A4
Authority
EP
European Patent Office
Prior art keywords
elf
polynucleotide
truncated
cancer cells
induce apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09812189A
Other languages
German (de)
French (fr)
Other versions
EP2331142A2 (en
Inventor
John E Thompson
Zhong Sun
Catherine Taylor
Richard Dondero
Zhenyu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eloxx Pharmaceuticals Inc
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/400,742 external-priority patent/US8703929B2/en
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of EP2331142A2 publication Critical patent/EP2331142A2/en
Publication of EP2331142A4 publication Critical patent/EP2331142A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP09812189A 2008-09-03 2009-09-02 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells Withdrawn EP2331142A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9374908P 2008-09-03 2008-09-03
US12/400,742 US8703929B2 (en) 2008-03-07 2009-03-09 Compositions comprising siRNA and plasmids
PCT/US2009/055791 WO2010028093A2 (en) 2008-09-03 2009-09-02 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
EP2331142A2 EP2331142A2 (en) 2011-06-15
EP2331142A4 true EP2331142A4 (en) 2012-08-29

Family

ID=41797839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09812189A Withdrawn EP2331142A4 (en) 2008-09-03 2009-09-02 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells

Country Status (8)

Country Link
EP (1) EP2331142A4 (en)
JP (1) JP2012501650A (en)
CN (1) CN102202693A (en)
AR (1) AR073274A1 (en)
AU (1) AU2009288092A1 (en)
CA (1) CA2735823A1 (en)
TW (1) TW201023898A (en)
WO (1) WO2010028093A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012165672A (en) * 2011-02-10 2012-09-06 Tottori Univ Artificial nucleic acid conjugate for amplifying single-base recognition ability
JP2015500808A (en) * 2011-11-30 2015-01-08 セネスコ テクノロジーズ，インコーポレイティド Treatment of B-cell lymphoma
EP2822601A4 (en) * 2012-03-08 2016-01-13 Univ Western Australia Micrornas and uses thereof
CN103709238B (en) * 2013-12-18 2015-04-22 北京市农林科学院 Application of poplar salt tolerant gene PtoeIF5A1
CN107110848B (en) 2014-11-07 2020-04-07 藤仓化成株式会社 Method for detecting arteriosclerosis and cancer using deoxyhypusine synthase gene as index
AU2016258326A1 (en) * 2015-05-05 2017-11-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
CN114231551B (en) * 2021-12-24 2023-09-29 云南大学 Application of protein in promoting apoptosis of insect lymphocytes and/or preventing and controlling pests

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060823A2 (en) * 2004-12-03 2006-06-08 Senesco Technologies, Inc. Apoptosis-specific eif-5a and polynucleotides encoding same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070824A2 (en) * 2005-12-13 2007-06-21 Senesco Technologies, Inc. Use of eif-5a to kill multiple myeloma cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060823A2 (en) * 2004-12-03 2006-06-08 Senesco Technologies, Inc. Apoptosis-specific eif-5a and polynucleotides encoding same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010028093A2 *
VERIDIANA S P CANO ET AL: "Mutational analyses of human eIF5A-1 - identification of amino acid residues critical for eIF5A activity and hypusine modification", FEBS JOURNAL, BLACKWELL PUBLISHING, LONDON, GB, vol. 275, no. 1, 1 January 2008 (2008-01-01), pages 44 - 58, XP008144924, ISSN: 1742-464X, DOI: 10.1111/J.1742-4658.2007.06172X *

Also Published As

Publication number Publication date
WO2010028093A2 (en) 2010-03-11
JP2012501650A (en) 2012-01-26
CA2735823A1 (en) 2010-03-11
EP2331142A2 (en) 2011-06-15
AR073274A1 (en) 2010-10-28
CN102202693A (en) 2011-09-28
AU2009288092A1 (en) 2010-03-11
WO2010028093A3 (en) 2010-08-05
TW201023898A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
GB0915782D0 (en) Improvements in or relating to pointing devices
GB0817175D0 (en) Improvements in relation to electrowetting elements
EP2331142A4 (en) Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
IL207071A0 (en) Selective photostimulation to induce cell proliferation
EP2271325A4 (en) Methods and use of inducing apoptosis in cancer cells
ZA201201981B (en) Cancer cell apoptosis
GB0905657D0 (en) Improvements in or relating to stairlifts
GB2475483B (en) Improvements in relation to mesh-sided trailers
GB0915732D0 (en) Improvements in or relating to exfoliation
ZA201201369B (en) Improvements in and relating to cable-barriers
EP2461813A4 (en) Compositions and methods for inducing apoptosis in prostate cancer cells
GB0909994D0 (en) Improvements in or relating to stairlifts
GB2490065B (en) Improvements in or relating to holography
GB0907916D0 (en) Improvements in or relating to graphical user interfaces
GB0918192D0 (en) Improvements to liquid rollerball and combined applicators
GB0916002D0 (en) Improvements in or relating to storage
GB0906505D0 (en) Improvements in or relating to storage
GB0906503D0 (en) Improvements in or relating to storage
GB0916003D0 (en) Improvements in or relating to storage
GB0916004D0 (en) Improvements in or relating to storage
GB201003351D0 (en) Improvements in or relating to microcontrollers
GB0905227D0 (en) Improvements in or relating to footwear
GB0702003D0 (en) Improvements in relation to cancer therapy
GB0912720D0 (en) Improvements in or relating to brush-storage devices
GB0902566D0 (en) Improvements in or relating to multiplexers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110401

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120731

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7105 20060101ALI20120725BHEP

Ipc: A61P 35/00 20060101ALI20120725BHEP

Ipc: A61K 39/235 20060101ALI20120725BHEP

Ipc: A61K 48/00 20060101AFI20120725BHEP

17Q First examination report despatched

Effective date: 20130918

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150427

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150908